CN102526714B - Medicine composition for curing tumour and preparation method thereof - Google Patents
Medicine composition for curing tumour and preparation method thereof Download PDFInfo
- Publication number
- CN102526714B CN102526714B CN 201110246529 CN201110246529A CN102526714B CN 102526714 B CN102526714 B CN 102526714B CN 201110246529 CN201110246529 CN 201110246529 CN 201110246529 A CN201110246529 A CN 201110246529A CN 102526714 B CN102526714 B CN 102526714B
- Authority
- CN
- China
- Prior art keywords
- tumor
- ranpirnase
- preparation
- medicine
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a medicine composition for curing tumour and a preparation method thereof, which is prepared by sodium cantharidinate, dihydroartemisinin, leopard frog enzyme and auxiliary materials. The medicine composition can improve immunity of organisms, directly kills tumour cells, is obvious in effects, is lower in toxicity and side effects compared with traditional chemoradiotherapy medicine, can serve as substitution medicine or important biological medicine for curing cancer, and brings good news to cancer patients.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of tumor and preparation method thereof, belong to field of pharmaceutical technology.
Background technology
Tumor is the even serious disease of life of harm humans health always, and tumor causes difficulty in life to the patient, and sensual misery is brought a series of problem and serious loss to country again.Since 1996, the annual tumour patient of newly making a definite diagnosis in the whole world is all more than 1,000 ten thousand, dead more than 700 ten thousand, to 1999 the end of the year whole world tumour patient sum exceeded 4,000 ten thousand.By 2000, according to Information Center, Ministry of Health's data, the city mortality of malignant tumors rose by a relatively large margin, than amplification before 10 years, was 30.24%.But because the expense for the treatment of tumor is very expensive, and case fatality rate is very high, and many less developed countries and regional patient understand abandoning cure, therefore the actual quantity of global tumor patient is greater than above numeral.
Antitumor drug market is the impetus of increase year after year in recent years, and overall increase trend and the tumor invasion person of tumour patient are rejuvenation trend at present, and the demand for the novel tumor curative sharply rises clinically.The average rate of increase of antineoplastic agent is higher than 12%, the rate of increase that is much higher than other large class medicine annuals 8%, because tumour patient increases year by year, cancer is not a kind of disease in addition, and most antitumor drug toxic and side effects are larger, therefore clinically must coupling multi-medicament Comprehensive Treatment.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of pharmaceutical composition for the treatment of tumor, and another technical problem to be solved by this invention is to provide a kind of preparation method for the treatment of the pharmaceutical composition of tumor.
For solving above technical problem, the present invention is by the following technical solutions: a kind of pharmaceutical composition for the treatment of tumor, described compositions is calculated according to components by weight percent, by disodium cantharidinate 0.1-10 part, dihydroarteannuin 5-150 part, ranpirnase 0.01-10 part and adjuvant, is prepared from.
Preferably, the pharmaceutical composition of described treatment tumor, described compositions is calculated according to components by weight percent, by disodium cantharidinate 0.5-5 part, dihydroarteannuin 50-100 part, ranpirnase 0.1-5 part and adjuvant, is prepared from.
Preferred, the pharmaceutical composition of described treatment tumor, described compositions is calculated according to components by weight percent, by 2 parts of disodium cantharidinates, 60 parts of dihydroarteannuins, 0.5 part of ranpirnase and adjuvant, is prepared from.
The pharmaceutical composition for the treatment of tumor of the present invention is prepared from by the following method: disodium cantharidinate, dihydroarteannuin and ranpirnase, according to definite ratio mix homogeneously, then are prepared into to conventional formulation according to conventional method.
Described conventional formulation refers to any pharmaceutically useful dosage form, and these dosage forms are selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, syrup, drop pill, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ejection preparation, freeze-dried powder, high-capacity injection, suppository, ointment, plaster, cream, spray, patch.
The preferred dosage form of the present invention is injection, injection freeze-dried powder, high-capacity injection, hard capsule, soft capsule, tablet, granule or pill.
Pharmaceutical composition of the present invention, when being prepared into pharmaceutical preparation, can add the acceptable adjuvant of some medicines as required, can adopt the galenic pharmacy routine techniques to prepare this pharmaceutical preparation, as the acceptable adjuvant of pharmaceutically active substance and medicine is mixed.The acceptable adjuvant of described medicine is selected from: mannitol, sorbitol, sorbic acid or potassium salt, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitamin C, vitamin E, vitamin D, azone, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, soil temperature 60-80, span-80, Cera Flava, lanoline, liquid paraffin, hexadecanol, gallate ester, agar, triethanolamine, basic amino acid, carbamide, allantoin, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, starch, magnesium stearate, low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, Mentholum, Oleum Glycines, ethyl cellulose, Semen Maydis oil, refined honey etc.
Pharmaceutical preparation of the present invention is determined usage and dosage according to patient's situation in use.
Pharmaceutical composition of the present invention, when making medicament, the medicament of unit dose can contain pharmaceutically active substance 0.1-1000mg of the present invention, and all the other are pharmaceutically acceptable adjuvant.Pharmaceutically acceptable adjuvant can be the 0.1-99.9% of total formulation weight amount by weight.
The present invention selects disodium cantharidinate, dihydroarteannuin and ranpirnase prescription, makes the pharmaceutical composition for the treatment of tumor.Disodium cantharidinate is the semi-synthetic derivant of cantharidin, and its molecular formula is C
10h
12o
5na
2, molecular weight is 258.1.With cantharidin, compare, its toxicity, zest are less, have especially obviously reduced the toxic and side effects of urinary system.Pharmacological evaluation shows, disodium cantharidinate can directly enter core and the kernel of Mouse Liver and Ascites Hepatoma Cell, and in anticancer, the infiltration of DNA and rna content and precursor, prove that it acts on the nucleic acid metabolism of cancerous cell, then make the cancerous cell morphology and function change, kill cancerous cell; Disodium cantharidinate also can reduce tumor cell cAMP phosphodiesterase activity, improves activity of catalase; Disodium cantharidinate can also stimulate medulla hematopoietic system, leukocyte increasing; Clinical in tumor and low leukocyte counts diseases such as primary hepatocarcinoma, also can be used for hepatitis, liver cirrhosis and hepatitis b virus carrier.One of important derivatives that dihydroarteannuin is arteannuin, its molecular formula is C
15h
24o
5, molecular weight is 284.35.A large amount of the pharmacological results demonstrations, the anti-tumor activity of dihydroarteannuin is strong, but the toxicity of normal tissue cell is very low, and its antitumaous effect characteristics are: 1, inhibition tumor cell propagation, inducing apoptosis of tumour cell; 2, mediate the direct killing cancerous cell by Fe, especially improve the lethal effect to the drug-resistant tumor cell; 3, suppress tumor-blood-vessel growth; Disturb tumor vascular new life in inhibition tumor cell increment differentiation, thereby cut off the demand that tumor cell obtains nutrient substance; 4, the collaborative reversing tumor drug resistance that reaches of chemicotherapy, dihydroarteannuin is the drug resistance of reversing tumor cell to traditional chemotherapeutics effectively, can increase the radiosensitivity of neuroglial cytoma simultaneously.Ranpirnase (ranpimase, commodity are called Onconase), it is a kind of nuclease extracted in the leopard Rana ovum, by 104 amino acid residues, formed, relative molecular mass is 11835, and isoelectric point, IP is 9.7, is single domain albumen minimum in known pancreatic ribonuclease superfamily member.Ranpirnase kills and wounds kinds of tumors is selective, but little to normal impact cell, and it does not damage bone marrow, also is difficult for causing drug resistance.Clinical research shows, it is similar that the ranpirnase mechanism of action in vivo and RNA disturb, and his tRNA that can degrade specifically, to rRNA and not effect of mRNA.
The present invention selects disodium cantharidinate, dihydroarteannuin and ranpirnase to carry out prescription and makes cancer therapy drug, successful, the more important thing is that the three all is taken from natural plants and animal body, toxicity and untoward reaction are well below traditional radiotherapy and chemotherapy medicine, and the three share and is expected to become the alternative medicine for the treatment of of cancer or important bio-pharmaceutical.In addition, the applicant finds under study for action, the effect that Synergistic is arranged after above medicament composing prescription, the curative effect of medication of making is better than the disodium cantharidinate injection, also is better than the injection that dihydroarteannuin and ranpirnase prescription are made, and medicine of the present invention is except the growth of energy inhibition tumor cell, and the effect of its enhancing human body immunity power is also very obvious.
The applicant has carried out pharmacodynamic experiment research to medicine of the present invention, and experimental result is as follows:
Experimental example 1: antitumor action research
1 experiment material:
1.1 medicine:
Injection of the present invention: get disodium cantharidinate 2mg, dihydroarteannuin 60mg and ranpirnase 0.5mg and mix, add water for injection to 1000ml, make injection;
Control drug 1: the disodium cantharidinate injection, commercially available, with 10 times of water for injection dilutions;
Control drug 2: get dihydroarteannuin 80mg and ranpirnase 8mg and mix, add water for injection to 1000ml, make injection;
1.2 tumor strain: murine sarcoma S
180, H
22.Animal: Kunming mouse, 18-24g.
2 methods and result: to the inhibitory action of animal transplanting tumor: 1. to mice S
180inhibitory action: getting go down to posterity the inoculation 7～10d tumor source animal, extract ascitic tumor fluid under aseptic condition, the right axil subcutaneous vaccination 1 * 10 of every Mus
6oncocyte, random packet start administration after 24h, every day, lumbar injection was 1 time, continuous 9～11d.Matched group lumbar injection sterile saline.Next day is put to death mice in drug withdrawal, weighs and peels off the subcutaneous tumors piece, claims the tumor weight, calculates tumour inhibiting rate, the results are shown in Table 1.Visible injection of the present invention has obvious inhibition S
180growth, and be good dose-effect relationship.2. to mice H
22inhibitory action: method is the same, every Mus inoculation 1 * 10
6h
22cell, the results are shown in Table 2.
Table 1 couple mice S
180inhibitory action
As known from Table 1, medicine group of the present invention is compared with the normal saline group, and significant differences is arranged, and P<0.01 illustrates that medicine of the present invention is to mice S
180the effect of inhibition is arranged; Medicine group of the present invention has been compared remarkable statistical significance with 1 group of control drug, and, with 2 groups of ratios of control drug, also there is significant difference P<0.05, and P<0.05, illustrate that medicine of the present invention is to mice S
180inhibitory action be better than control drug 1 and control drug 2.
Table 2 couple mice H
22inhibitory action
As known from Table 2, medicine group of the present invention is compared with the normal saline group, and significant differences is arranged, and P<0.01 illustrates that medicine of the present invention is to mice H
22the effect of inhibition is arranged; Medicine group of the present invention has been compared remarkable statistical significance with 1 group of control drug, and, with 2 groups of ratios of control drug, also there is significant difference P<0.05, and P<0.05, illustrate that medicine of the present invention is to mice H
22inhibitory action be better than control drug 1 and control drug 2.
3 conclusions: according to above experimental result, visible medicine of the present invention is to mice S
180with mice H
22have obvious inhibitory action, its effect is better than control drug 1 and control drug 2.
Experimental example 2: on the impact of lymphocyte subgroup
1 experiment material:
1.1 animal: 4～5 week age the SD rat, body weight (112.7 ± 15.7) g, male and female dual-purpose.
1.2 tumor strain: colorectal cancer cells (L
0v
0strain).
1.3 medicine:
Injection of the present invention: get disodium cantharidinate 2mg, dihydroarteannuin 60mg and ranpirnase 0.5mg and mix, add water for injection to 1000ml, make injection;
Control drug 1: the disodium cantharidinate injection, commercially available, with 10 times of water for injection dilutions;
Control drug 2: get dihydroarteannuin 80m g and ranpirnase 8mg and mix, add water for injection to 1000ml, make injection;
2 methods and result: the conventional inoculation of SD rat abdominal cavity colorectal cancer L
0v
0cell suspension 0.2ml approximately 1 * 10
6oncocyte, be divided into 4 groups at random after one week, and 10 every group, intravenously administrable, once a day, continuous one week.After drug withdrawal, adopt peripheral blood and put to death rat next day, get 10ul ascites and add normal saline 1.99ml dilution, count and calculate contained tumor cell number and every high power field karyokinesis number in every liter of ascites, and obtain growth of tumour cell suppression ratio and every high power field karyokinesis suppression ratio, with CD3 in the cells were tested by flow cytometry peripheral blood
+, CD4
+, CD8
+, calculate CD4
+/ CD8
+ratio.
Inhibitory rate of cell growth %=(the average oncocyte number of 1-experimental group/equal oncocyte number of matched group product) * 100%
Karyokinesis suppression ratio %=(1-experimental group average core division number/matched group average core division number) * 100%
The impact (x ± s) of table 3 on the t lymphocyte subset group
As known from Table 3, medicine group of the present invention is compared with the normal saline group, t lymphocyte subset group CD3
+, CD4
+, CD4
+/ CD8
+all higher than normal saline group, CD8
+all, lower than the normal saline group, both comparing differences have utmost point significance, P<0.01; 2 groups of medicine group of the present invention and 1 group of control drug and control drug are compared, t lymphocyte subset group CD3
+, CD4
+, CD4
+/ CD8
+all higher than control drug group, CD8
+all, lower than the control drug group, difference has significance, P<0.05; The effect that medicine enhancing human body immunity function of the present invention is described is better than control drug 1 and control drug 2.
3 conclusions: T lymphocytic infiltration degree directly reflects body antineoplastic state.According to above experimental result, the effect that visible medicine of the present invention has obvious enhancing human body immunity function, and its effect is better than control drug 1 and control drug 2.
Beneficial effect: compared with prior art, the present invention selects disodium cantharidinate, dihydroarteannuin and ranpirnase prescription, and the effect of Synergistic is arranged, the medicine of making can improve the immunologic function of body, can directly press down tumor killing cell again, effect is remarkable, has reached goal of the invention.
The specific embodiment:
Further illustrate by the following examples the present invention, but not as limitation of the present invention.
Embodiment 1
Prescription: disodium cantharidinate 20mg, dihydroarteannuin 600mg, ranpirnase 5mg
The preparation technology of described injection is: get above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and mix, add water for injection to 1000ml, with the filtering with microporous membrane of 0.45 μ m, stir and within 20 minutes, make mix homogeneously, embedding, sterilizing obtain ejection preparation.
Usage and dosage: intravenous injection or intravenous drip, a 5-20ml, 1 time on the one.
Embodiment 2
Prescription: disodium cantharidinate 50mg, dihydroarteannuin 500mg, ranpirnase 1mg
Preparation technology is: get above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and glycerol 250ml lactose 100g mannitol 150g mix homogeneously, inject water to 1000ml, regulating liquid PH value is 7, filter, and fill, lyophilization, obtain freeze-dried powder.Freeze-dry process is: fill is sent into to freeze dryer after good cillin bottle half tamponade, slowly be refrigerated to below-15 ℃, be evacuated to 5-10Pa, control heat temperature raising speed is no more than 4 ℃/h and is distilled, distil after 10 hours, set shelf temperature and be 20 ℃ and carry out dryly for the second time, when products temperature and shelf temperature approach, steady temperature is the total head plug after dry 0.5-1 hour.
Usage and dosage: intravenous injection or intravenous drip, a 0.5-5mg, 1 time on the one.After dissolving with 0.9% sodium chloride or 5～10% glucose injections, instil.
Embodiment 3
Prescription: disodium cantharidinate 10g, dihydroarteannuin 5g, ranpirnase 0.01g
Preparation technology is: get above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and mix, add sodium chloride 10Kg to mix simultaneously, add water for injection to 100L, regulate PH6, with the filtering with microporous membrane of 0.22 μ m, stir and within 20 minutes, make mix homogeneously, packing, sterilizing, obtain high-capacity injection.
Usage and dosage: intravenous injection or intravenous drip, a 500-1000ml, 1 time on the one.
Embodiment 4
Prescription: disodium cantharidinate 0.5g, dihydroarteannuin 100g, ranpirnase 5g
Preparation technology is: gets above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and mixes, add starch 150g, Pulvis Talci 100g, mix, and spray drying, granulate, incapsulate, and makes 2000, obtains capsule.
Usage and dosage: oral, 2 times on the one, one time 1.
Embodiment 5
Prescription: disodium cantharidinate 0.1g, dihydroarteannuin 150g, ranpirnase 10g
Preparation technology is: get above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and 400g starch, the 100g microcrystalline Cellulose is put into mixing and blending machine; mix 30min; add starch slurry (10%) 500g to make soft; cross 14 order nylon mesh through oscillating granulator and granulate, drying, dry granule and magnesium stearate 50g are always mixed; granulate; be pressed into 2000, sugar coating or film-coat, obtain tablet.
Usage and dosage: oral, 2 times on the one, one time 1.
Embodiment 6
Prescription: disodium cantharidinate 0.5g, dihydroarteannuin 50g, ranpirnase 0.1g
Preparation technology is: get above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and mix, separately get Oleum Glycines 300ml, tween 80 180ml, ethyl cellulose 200g mix homogeneously, above-mentioned medicated powder is joined in mixed liquor and makes to be uniformly dispersed, make 1000 balls, obtain soft capsule.
Usage and dosage: oral, 1 time on the one, one time 1.
Embodiment 7
Prescription: disodium cantharidinate 5g, dihydroarteannuin 100g, ranpirnase 5g
Preparation technology is: get above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and mix, separately get sucrose 9000g and be dissolved in boiling water, mix homogeneously with above-mentioned medicated powder, granulate, drying, obtain granule.
Usage and dosage: oral, 2 times on the one, a 2-5g.
Embodiment 8
Prescription: disodium cantharidinate 1g, dihydroarteannuin 15g, ranpirnase 1g
Preparation technology is: get above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and mix, then add simple syrup 200g, sodium benzoate 1g, boil dissolving, add water to 1000ml, stir evenly, filter, embedding, obtain oral liquid.
Usage and dosage: oral, 2 times on the one, a 5ml.
Embodiment 9
Prescription: disodium cantharidinate 0.1g, dihydroarteannuin 5g, ranpirnase 0.01g
Preparation technology is: gets above-mentioned disodium cantharidinate, dihydroarteannuin and ranpirnase and mixes, will after PEG400 200g melting, add mix homogeneously in above drug powder, and cooling in splashing in methyl-silicone oil, make 1000 balls, obtain drop pill.
Usage and dosage: oral, 1 time on the one, one time 1.
Claims (4)
1. a pharmaceutical composition for the treatment of tumor, it is characterized in that: the pharmaceutical composition of described treatment tumor calculates according to components by weight percent, by 2 parts of disodium cantharidinates, 60 parts of dihydroarteannuins, 0.5 part of ranpirnase and adjuvant, is prepared from.
2. the method for the pharmaceutical composition of tumor is treated in preparation as claimed in claim 1, it is characterized in that: disodium cantharidinate, dihydroarteannuin and ranpirnase, according to definite ratio mix homogeneously, then are prepared into to conventional formulation according to conventional method.
3. the method for the pharmaceutical composition of preparation treatment tumor according to claim 2, it is characterized in that: described conventional formulation is selected from: tablet, hard capsule, soft capsule, oral liquid, drop pill, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, ejection preparation, freeze-dried powder, suppository, cream, spray or patch.
4. prepare according to claim 3 the method for the pharmaceutical composition for the treatment of tumor, it is characterized in that: described conventional formulation is injection, injection freeze-dried powder, hard capsule, soft capsule, tablet, granule or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110246529 CN102526714B (en) | 2011-08-24 | 2011-08-24 | Medicine composition for curing tumour and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110246529 CN102526714B (en) | 2011-08-24 | 2011-08-24 | Medicine composition for curing tumour and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526714A CN102526714A (en) | 2012-07-04 |
| CN102526714B true CN102526714B (en) | 2013-12-25 |
Family
ID=46335529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110246529 Active CN102526714B (en) | 2011-08-24 | 2011-08-24 | Medicine composition for curing tumour and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526714B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285381B (en) * | 2012-02-22 | 2015-06-24 | 贵州神奇集团 | A combination of ribonucleases and cantharidin |
| CN102920702B (en) * | 2012-11-19 | 2013-09-25 | 贵州金桥药业有限公司 | Dihydroartemisinin and Chinese blister beetle composition, enteric preparation and application and preparation thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101217956A (en) * | 2005-05-05 | 2008-07-09 | 康宾纳特克斯公司 | Compositions and methods for treatment for neoplasms |
| WO2009112522A1 (en) * | 2008-03-12 | 2009-09-17 | 4Sc Ag | (E)-N-(2-Amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts |
-
2011
- 2011-08-24 CN CN 201110246529 patent/CN102526714B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101217956A (en) * | 2005-05-05 | 2008-07-09 | 康宾纳特克斯公司 | Compositions and methods for treatment for neoplasms |
| WO2009112522A1 (en) * | 2008-03-12 | 2009-09-17 | 4Sc Ag | (E)-N-(2-Amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts |
Non-Patent Citations (6)
| Title |
|---|
| 何庆 等.豹蛙酶研究进展.《生物技术通讯》.2008,第19卷(第5期),760-762. |
| 双氢青蒿素抗肿瘤作用研究进展;汪溪 等;《海南医学》;20101231;第21卷(第13期);119-121 * |
| 斑蝥酸钠抗肿瘤作用的临床疗效评价;高雪艳 等;《海峡药学》;20081231;第20卷(第5期);89-90 * |
| 汪溪 等.双氢青蒿素抗肿瘤作用研究进展.《海南医学》.2010,第21卷(第13期),119-121. |
| 豹蛙酶研究进展;何庆 等;《生物技术通讯》;20081231;第19卷(第5期);760-762 * |
| 高雪艳 等.斑蝥酸钠抗肿瘤作用的临床疗效评价.《海峡药学》.2008,第20卷(第5期),89-90. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526714A (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112789059A (en) | Use of amino acid nutrients and pharmaceutical compositions containing same | |
| CN111375064A (en) | Pharmaceutical composition for chemotherapy and immunization combination treatment | |
| CN111375062A (en) | Biopolymer pharmaceutical composition for in-situ gel-forming chemotherapy and immune combination therapy | |
| CN101947234A (en) | Preparation method for preparation containing glucosamine and application thereof | |
| CN111375065A (en) | Biopolymer pharmaceutical composition for tumor treatment | |
| CN110870868A (en) | Pharmaceutical composition containing methylene blue dye, nutrient or/and anti-tumor compound and application thereof | |
| US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| CN102475698B (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN102526714B (en) | Medicine composition for curing tumour and preparation method thereof | |
| WO2022068918A1 (en) | Pharmaceutical composition comprising acid-base neutralization combination and application thereof | |
| CN110870918A (en) | Pharmaceutical composition containing amino acid nutrients and antitumor chemotherapeutic drugs and application thereof | |
| CN102716465B (en) | Pharmaceutical composite for treating tumor and preparation method of pharmaceutical composite | |
| CN112438942A (en) | Pharmaceutical composition containing alkalizer and its synergist and its application | |
| CN106565718B (en) | Selenium-containing compound and application thereof | |
| CN110870858A (en) | Pharmaceutical compositions comprising organic acid acidifying agents and conventional ineffective compounds and uses thereof | |
| CN102698256B (en) | Medicine composition for treating tumor and preparation method for medicine composition | |
| CN100377712C (en) | Cucurbitacin lipsome preparation method and formulation | |
| CN105769849B (en) | A kind of pharmaceutical composition for treating oophoroma | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof | |
| CN102727867B (en) | Antineoplastic pharmaceutical composition and application thereof, kit and package | |
| CN102698252B (en) | Medicine composition for treating tumor and preparation method for medicine composition | |
| CN101559037B (en) | Binary solution type preparation for intravenous injection and intracerebral injection | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN105769884B (en) | A kind of pharmaceutical composition for treating lung cancer | |
| CN100525782C (en) | Tetraselmis chui polysaccharide protein possessing antineoplastic function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180608 Address after: 550000 Beijing Road, Yunyan District, Guiyang, Guizhou Province, No. 1 Patentee after: Guizhou Shenqi Drug Research Institute Address before: No. 1 Beijing Road, Guiyang, Guizhou Patentee before: Guizhou Maojka Group Holding Co., Ltd. |